Provided by Tiger Trade Technology Pte. Ltd.

ABBISKO-B

11.860
+0.0700.59%
Volume:2.00M
Turnover:23.94M
Market Cap:7.97B
PE:118.00
High:12.470
Open:11.790
Low:11.680
Close:11.790
52wk High:19.780
52wk Low:5.520
Shares:672.00M
HK Float Shares:672.00M
Volume Ratio:3.72
T/O Rate:0.30%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.101
ROE:2.85%
ROA:0.78%
PB:3.65
PE(LYR):118.00
PS:11.46

Loading ...

Stock Track | ABBISKO-B Soars 5.83% Intraday on Clinical Trial Milestone and CEO Share Purchase

Stock Track
·
Mar 04

Abbisko Cayman (2256) Announces First Patient Dosing of Oral KRAS G12D Inhibitor ABSK141

Bulletin Express
·
Mar 04

ABBISKO-B Initiates First Patient Dosing in Phase I/II Trial for Oral KRAS G12D Inhibitor ABSK141

Stock News
·
Mar 04

Abbisko Therapeutics Doses First Patient in ABSK141 Phase I/II Trial

Reuters
·
Mar 04

BRIEF-Abbisko Cayman Says CEO Purchased Total 45,000 Shares Of Co At Average Price HK$11.26 Per Share

Reuters
·
Mar 03

ABBISKO-B Founder and CEO Increases Holdings by 45,000 Shares

Stock News
·
Mar 03

Abbisko Cayman Limited (2256) Announces Shareholding Increase by Founder

Bulletin Express
·
Mar 03

Abbisko Cayman - CEO Purchased Total 45,000 Shares of Co in Open Market on March 3 at Average Price HK$11.26 per Share

THOMSON REUTERS
·
Mar 03

Abbisko Profit Nearly Doubles in 2025

MT Newswires Live
·
Mar 03

ABBISKO-B Reports Near 100% Profit Surge in Annual Results, Signaling Sustained Profitability and Commercialization Phase

Stock News
·
Mar 03

ABBISKO-B Reports Annual Revenue Growth of 21.45% to RMB 612 Million

Stock News
·
Mar 02

Abbisko Wins First China Drug Approval, Reshuffles Secretaries as Merck Deepens Tie-Up

TIPRANKS
·
Mar 02

Abbisko (2256) Releases 2025 Annual Financial Results and Announces Corporate Secretary Changes

Bulletin Express
·
Mar 02

Abbisko posts FY2025 profit of CNY55.2 million +95%

Reuters
·
Mar 02

Assessing Abbisko Cayman (SEHK:2256) Valuation After Irpagratinib Advances Into Global Phase I Trial

Simply Wall St.
·
Feb 24

Abbisko Cayman (2256) Schedules Board Meeting to Approve 2025 Annual Results

Bulletin Express
·
Feb 11

Abbisko Cayman Board to Approve Audited Annual Results and Consider Final Dividend

Reuters
·
Feb 11

Abbisko Unit Doses First U.S. Patient in Phase 1 Study of Liver Cancer Drug

MT Newswires Live
·
Feb 11

Abbisko Cayman Limited (2256) Announces First U.S. Patient Dosing in Global Phase I Irpagratinib Trial

Bulletin Express
·
Feb 11

Abbisko Therapeutics Doses First U.S. Patient in Global Phase I Study of Irpagratinib

Reuters
·
Feb 11